Omnicell, Inc. (NASDAQ:OMCL)’s share price hit a new 52-week high on Tuesday . The stock traded as high as $69.55 and last traded at $69.55, with a volume of 27763 shares changing hands. The stock had previously closed at $68.75.

OMCL has been the subject of several analyst reports. TheStreet raised Omnicell from a “c+” rating to a “b” rating in a report on Friday, July 27th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Omnicell in a report on Thursday, July 26th. BidaskClub cut Omnicell from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 12th. Benchmark initiated coverage on Omnicell in a report on Friday, June 29th. They issued a “buy” rating and a $63.00 price objective for the company. Finally, ValuEngine raised Omnicell from a “hold” rating to a “buy” rating in a report on Wednesday, June 20th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $53.80.

The company has a quick ratio of 1.27, a current ratio of 1.78 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $2.70 billion, a P/E ratio of 380.91, a price-to-earnings-growth ratio of 3.40 and a beta of 1.00.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 26th. The company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.07. Omnicell had a return on equity of 5.88% and a net margin of 5.27%. The company had revenue of $188.70 million during the quarter, compared to analysts’ expectations of $188.80 million. During the same quarter in the previous year, the firm earned $0.31 EPS. Omnicell’s revenue was up 4.3% on a year-over-year basis. equities research analysts anticipate that Omnicell, Inc. will post 1.35 earnings per share for the current year.

In other news, EVP Jorge R. Taborga sold 17,644 shares of the business’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $58.77, for a total transaction of $1,036,937.88. Following the completion of the transaction, the executive vice president now owns 44,973 shares of the company’s stock, valued at approximately $2,643,063.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director James T. Judson sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $58.76, for a total value of $293,800.00. Following the transaction, the director now directly owns 39,952 shares of the company’s stock, valued at approximately $2,347,579.52. The disclosure for this sale can be found here. Insiders have sold a total of 71,187 shares of company stock valued at $3,908,628 in the last three months. 3.71% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of OMCL. Bank of Montreal Can acquired a new position in Omnicell in the 2nd quarter worth about $102,000. SG Americas Securities LLC bought a new stake in shares of Omnicell in the 1st quarter valued at about $116,000. Pitcairn Co. bought a new stake in shares of Omnicell in the 1st quarter valued at about $203,000. Virtu Financial LLC bought a new stake in shares of Omnicell in the 2nd quarter valued at about $204,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of Omnicell in the 1st quarter valued at about $223,000. 98.80% of the stock is owned by institutional investors and hedge funds.

About Omnicell (NASDAQ:OMCL)

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Featured Article: Dividend

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.